The prevalence of internuclear ophthalmoparesis in a population-based cohort of individuals with multiple sclerosis.

Eye-Tracking technology Internuclear ophthalmoparesis Internuclear ophthalmoplegia Multiple sclerosis Ocular motility disorders Oculography Prevalence

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 07 02 2022
revised: 14 04 2022
accepted: 21 04 2022
pubmed: 2 5 2022
medline: 29 6 2022
entrez: 1 5 2022
Statut: ppublish

Résumé

Internuclear ophthalmoparesis (INO) occurs in 15-52% of individuals with multiple sclerosis (MS) and is reliably detected by infrared oculography. Methods for diagnosing INO with infrared oculography and the association between INO and MS characteristics need confirmation. We aimed to describe INO prevalence and the clinical characteristics of individuals with MS and INO in a population-based cohort of individuals with MS born in the year 1966 (Project Y). Previously described thresholds for the versional dysconjugacy index (VDI), assessed with standardized infrared oculography, were used to detect INO in participants of project Y. Clinical characteristics, visual functioning and complaints were compared between individuals with MS with INO and individuals with MS without INO. Two-hundred-twenty individuals with MS and 110 healthy controls were included. VDI values exceeding the threshold for INO presented in 53 (24%) individuals with MS and 19 controls (13%). INO was associated with male sex, greater disability, worse cognition and worse arm function in individuals with MS. There was no association with disease duration, visual functioning or complaints. INO is prevalent among individuals with MS aged fifty-three and related to clinical characteristics of MS. INO was more frequently detected in healthy controls than previous studies, implying that oculography based diagnosis of INO requires further refinement.

Sections du résumé

BACKGROUND BACKGROUND
Internuclear ophthalmoparesis (INO) occurs in 15-52% of individuals with multiple sclerosis (MS) and is reliably detected by infrared oculography. Methods for diagnosing INO with infrared oculography and the association between INO and MS characteristics need confirmation. We aimed to describe INO prevalence and the clinical characteristics of individuals with MS and INO in a population-based cohort of individuals with MS born in the year 1966 (Project Y).
METHODS METHODS
Previously described thresholds for the versional dysconjugacy index (VDI), assessed with standardized infrared oculography, were used to detect INO in participants of project Y. Clinical characteristics, visual functioning and complaints were compared between individuals with MS with INO and individuals with MS without INO.
RESULTS RESULTS
Two-hundred-twenty individuals with MS and 110 healthy controls were included. VDI values exceeding the threshold for INO presented in 53 (24%) individuals with MS and 19 controls (13%). INO was associated with male sex, greater disability, worse cognition and worse arm function in individuals with MS. There was no association with disease duration, visual functioning or complaints.
CONCLUSIONS CONCLUSIONS
INO is prevalent among individuals with MS aged fifty-three and related to clinical characteristics of MS. INO was more frequently detected in healthy controls than previous studies, implying that oculography based diagnosis of INO requires further refinement.

Identifiants

pubmed: 35490450
pii: S2211-0348(22)00336-4
doi: 10.1016/j.msard.2022.103824
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103824

Informations de copyright

Copyright © 2022. Published by Elsevier B.V.

Auteurs

S N Hof (SN)

Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Neurology, MS Center and Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands. Electronic address: s.n.hof@amsterdamumc.nl.

F C Loonstra (FC)

Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Neurology, MS Center and Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.

L R J de Ruiter (LRJ)

Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Neurology, MS Center and Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.

L J van Rijn (LJ)

Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Ophthalmology, Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Onze Lieve Vrouwe Gasthuis, Department of Ophthalmology, Amsterdam, The Netherlands.

A Petzold (A)

Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Neurology, MS Center and Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Ophthalmology, Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Moorfields Eye Hospital, The National Hospital for Neurology and Neurosurgery and the UCL Queen Square Institute of Neurology, London, United Kingdom.

B M J Uitdehaag (BMJ)

Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Neurology, MS Center and Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.

J A Nij Bijvank (JA)

Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Neurology, MS Center and Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Ophthalmology, Neuro-ophthalmology Expertise Center Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH